ConductScience.org, home

Paper119786

Description and classification of the newer cephalosporins and their relationships with the established compounds.

O'Callaghan CH. J Antimicrob Chemother, 1979. Cited by 100 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Description and classification of the newer cephalosporins and their relationships with the established compounds. Papers, record 119786. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/119786

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Description and classification of the newer cephalosporins and their relationships with the established compounds.
PubMed
Journal
J Antimicrob Chemother
PubMed
Year
1979
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
100
iCite
Relative citation ratio, by iCite
6.23
iCite
Revised in PubMed
2019-05-09
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1O'Callaghan CHC H

Source PubMed

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CephalosporinsMajor topic
Administration, Oral
Animal Diseases
Animals
Cephalosporinase
Drug Resistance, Microbial
Humans
Infusions, Parenteral
Injections, Intramuscular
Intestinal Absorption
Kinetics
Pseudomonas aeruginosa

Source PubMed

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 100 citations.

PMIDTitleJournalYearIn PapersSource
35,658,710Liverpool Epidemic Strain Isolates of Pseudomonas aeruginosa Display High Levels of Antimicrobial Resistance during Both Planktonic and Biofilm Growth.Microbiol Spectr2022https://conductscience.org/library/papers/35658710PubMed
29,769,008Biochemical and Haematological Predictors of Reduced Neutrophil Granulocyte Count associated with Intravenous Ceftriaxone Treatment.Rev Recent Clin Trials2018https://conductscience.org/library/papers/29769008PubMed
8,665,470beta-Lactamases in laboratory and clinical resistance.Clin Microbiol Rev1995https://conductscience.org/library/papers/8665470PubMed
7,247,358In vitro susceptibility of Mycobacterium fortuitum to cefoxitin.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/7247358PubMed
7,035,856Antibiotic resistance in pathogenic and producing bacteria, with special reference to beta-lactam antibiotics.Microbiol Rev1981https://conductscience.org/library/papers/7035856PubMed
6,974,539BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/6974539PubMed
6,972,734beta-Lactamases and resistance to cephalosporins.Antonie Van Leeuwenhoek1981https://conductscience.org/library/papers/6972734PubMed
6,972,194Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.Antimicrob Agents Chemother1980https://conductscience.org/library/papers/6972194PubMed
6,961,887In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins.Antimicrob Agents Chemother1982https://conductscience.org/library/papers/6961887PubMed
6,919,412Comparative in vitro study of temocillin (BRL 17421), a new penicillin.Antimicrob Agents Chemother1982https://conductscience.org/library/papers/6919412PubMed
6,800,462Twenty-one years of beating beta-lactamases.Br Med J (Clin Res Ed)1982https://conductscience.org/library/papers/6800462PubMed
6,742,815Antimicrobial activity of SK&F 88070, an expanded-spectrum cephalosporin with high and prolonged levels in blood.Antimicrob Agents Chemother1984https://conductscience.org/library/papers/6742815PubMed
6,604,496In vitro susceptibility of Mycobacterium fortuitum to amoxicillin or cephalothin in combination with clavulanic acid.Antimicrob Agents Chemother1983https://conductscience.org/library/papers/6604496PubMed
6,601,063The current state of cephalosporin antibiotics: microbiological aspects.Infection1983https://conductscience.org/library/papers/6601063PubMed
6,455,966Pharmacokinetics of cefoperazone in patients with neoplastic disease.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/6455966PubMed
6,335,134Selection of resistant mutants of Citrobacter freundii by second and third-generation cephalosporins and imipenem.Infection1984https://conductscience.org/library/papers/6335134PubMed
6,279,094Interaction between non-classical beta-lactam compounds and the Zn2+-containing G and serine R61 and R39 D-alanyl-D-alanine peptidases.Biochem J1981https://conductscience.org/library/papers/6279094PubMed
6,276,458Cefotaxime in treatment of meningitis and ventriculitis? Evaluation of drug concentrations in human cerebrospinal fluid.Intensive Care Med1982https://conductscience.org/library/papers/6276458PubMed
6,275,779Pharmacokinetics of ceftriaxone in humans.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/6275779PubMed
6,100,422Effects of ampicillin plus sulbactam on bowel flora in patients undergoing colorectal surgery.Antimicrob Agents Chemother1982https://conductscience.org/library/papers/6100422PubMed

See all 25 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/119786

GET https://conductscience.org/api/papers/v1/119786/cited_by?page=2